Follow this page and receive
notifications about new suppliers
Ixazomib API Manufacturers
compare suppliers & get competitive offers
Date | Seller | Exporter country | Buyer | Importer country | Product | Quantity (KG) | Price per KG | Latest transactions |
|---|---|---|---|---|---|---|---|---|
| 31-Jul-2024 | (Hidden) | 
India
| AZISTA BHU... | 
Bhutan
| IXAZOMIB C... | 0.30 | $ @36$-7! | Check all data |
| 25-Jul-2024 | (Hidden) | Czech | WATSON PHA... |
India
| IXAZOMIB C... | 0.25 | $ @36$-7! | |
| 13-Feb-2024 | (Hidden) | Czech | WATSON PHA... |
India
| IXAZOMIB C... | 0.10 | $ @36$-7! |
Filters
Reset current filters
Type
Production region
Qualifications
Country of origin
Follow us
Distributor
Produced in:
Established in: 2011
MOQ: 1 g
Employees: 10+
Fast Response and Good Communication
Willingness To Start From Small
Flexible Payment Terms
+ 0
All certificates
How does it work?
You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry
Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only
Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week
Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news
Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module
Looking for Ixazomib API 1072833-77-2?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Ixazomib. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Ixazomib
- Cas Number:
- 1072833-77-2
- DrugBank number:
- DB09570
- Unique Ingredient Identifier:
- 71050168A2
About Ixazomib
You can find a short description about Ixazomib here. Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple myeloma therapy) in the control of myeloma growth and prevention of bone loss. Ixazomib citrate is marketed by Takeda Pharmaceuticals under the brand name Ninlaro, which is a prodrug that becomes quickly converted to its active metabolite, ixazomib, after administration.
More information such as the structure, indication or toxicity is available on Drugbank, click the ID above.
Ixazomib is a type of Antineoplastics
Antineoplastics are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) primarily used in the treatment of cancer. These powerful substances inhibit or destroy the growth of cancer cells, thus impeding the progression of malignancies.
Antineoplastics exert their therapeutic effects through various mechanisms. Some APIs interfere with DNA replication, inhibiting the division and proliferation of cancer cells. Others target specific proteins or enzymes involved in tumor growth, effectively blocking their function. Additionally, certain antineoplastic agents induce programmed cell death, known as apoptosis, in cancer cells.
These APIs find application in a wide range of cancer treatments, including chemotherapy, targeted therapy, immunotherapy, and hormone therapy. They are often administered in combination with other drugs to optimize therapeutic outcomes and minimize drug resistance.
Antineoplastics are typically synthesized through complex chemical processes, ensuring high purity and potency. Stringent quality control measures are implemented throughout manufacturing to meet regulatory standards and ensure patient safety.
Although antineoplastics offer significant benefits in treating cancer, they can also cause adverse effects due to their cytotoxic nature. Common side effects include bone marrow suppression, gastrointestinal disturbances, hair loss, and immune system suppression. Close monitoring and supportive care are essential to manage these side effects effectively.
In conclusion, antineoplastics are a vital category of pharmaceutical APIs used in the treatment of cancer. Through their diverse mechanisms of action, these compounds play a critical role in combating malignancies and improving patient outcomes.
Ixazomib manufacturers | traders | suppliers
We have 1 companies offering Ixazomib produced in 1 different countries.
Get in contact with the supplier of your choice:
- Shandong Octagon Chemicals Limited from China, product country of origin China
Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.
You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.
